Stem Cell Therapy for Type 1 Diabetes: The VX-880 Era and What It Means
Type 1 diabetes research is in the middle of a genuine scientific revolution. For the first time in history, stem cell-derived islet cells have enabled some patients to produce their own insulin again. But the gap between clinical trial breakthroughs and what is commercially available — especially abroad — remains enormous. Here is an honest status report.
Two Very Different Approaches
The confusion in this space stems from two completely different strategies both being called "stem cell therapy for diabetes." They are not interchangeable.
| Factor | Islet Cell Replacement (VX-880/Donislecel) | MSC Immunomodulation |
|---|---|---|
| Goal | Replace destroyed beta cells | Reduce autoimmune attack on remaining cells |
| Cell type | Pluripotent stem cell-derived islet cells | Mesenchymal stem cells (MSC) |
| Administration | Hepatic portal vein infusion (surgical) | IV infusion (outpatient) |
| Immunosuppression required | Yes — lifelong anti-rejection drugs | No |
| Evidence level | Level 2 (Phase I/II trial data) | Level 3 (case series, small trials) |
| Insulin independence achieved? | Yes, in select trial patients | No — may reduce insulin dose |
| Availability | Clinical trials only (US, select sites) | Commercial clinics (Colombia, others) |
| Cost | Unknown (trial-only) | $8,000–$18,000 (Colombia) |
The VX-880 Breakthrough
Vertex Pharmaceuticals' VX-880 program represents the most significant advance in Type 1 diabetes in decades. In the Phase I/II trial, patients with severe hypoglycemia unawareness and undetectable C-peptide (meaning zero endogenous insulin production) received stem cell-derived islet cells infused into the liver's portal vein.
Results published through 2025–2026 showed that several patients achieved clinically meaningful insulin independence — they stopped using exogenous insulin entirely. C-peptide levels (measuring endogenous insulin production) became detectable and, in some cases, normalized. HbA1c levels improved to target ranges without insulin injections.
VX-880 results are genuinely revolutionary for Type 1 diabetes science. However, this therapy requires lifelong immunosuppression, is available only through clinical trials at select US medical centers, and is years from commercial availability. It is not what clinics abroad are offering.
MSC Therapy for T1D: The Realistic Picture
What regenerative medicine clinics offer for Type 1 diabetes is mesenchymal stem cell therapy — a fundamentally different approach. The rationale: MSCs can modulate the autoimmune process, potentially slowing the destruction of remaining beta cells and creating a more favorable environment for any surviving islets.
Published evidence from small trials (primarily from Sweden and China) suggests MSC infusion in newly diagnosed T1D patients may preserve some residual C-peptide production for longer than placebo, and some patients experienced modest reductions in insulin requirements. However, no published study has shown MSC therapy enabling insulin independence in established T1D.
Aggregated from Carlsson et al. (2015), Cai et al. (2016), and Hu et al. (2022). Results most significant in recently diagnosed patients.
Critical Distinction: New-Onset vs. Established T1D
Timing matters enormously. Published MSC research shows the strongest benefit in patients within the first year of T1D diagnosis, when residual beta cell mass still exists to protect. In patients with established T1D (5+ years, undetectable C-peptide), there are essentially no functional beta cells left for MSCs to protect. The immunomodulatory benefit on beta cells is irrelevant when no beta cells remain.
If you have had Type 1 diabetes for more than 2–3 years and have undetectable C-peptide levels, MSC therapy is extremely unlikely to reduce your insulin requirements based on all published evidence. Any clinic promising insulin reduction or independence in this population is not supported by the science.
Colombia Treatment Considerations
Colombian clinics offering MSC protocols for Type 1 diabetes typically administer IV infusions of culture-expanded umbilical-cord-derived MSCs, often in 2–4 session protocols. Costs range from $8,000 to $18,000. These protocols target immunomodulation and general metabolic support — not beta cell replacement.
For patients with recent-onset T1D (<1 year) who retain measurable C-peptide, there is a reasonable scientific basis to explore MSC therapy as a complement to insulin therapy, with the goal of preserving residual beta cell function. For patients with established T1D, the evidence does not support this approach for glucose management.
Frequently Asked Questions
No stem cell therapy currently cures T1D. VX-880 achieved insulin independence in trial patients, but those patients require lifelong immunosuppression, and the therapy is years from commercial availability. MSC therapy cannot achieve insulin independence in established T1D.
No. VX-880 (donislecel) is available only through Vertex's clinical trial program at select US medical centers. It is not available commercially anywhere in the world as of mid-2026. What Colombian clinics offer is MSC therapy, a different approach.
There is Level 3 evidence suggesting MSC infusion within the first year of diagnosis may help preserve residual beta cell function. This is a reasonable discussion to have with your endocrinologist, though it should complement (not replace) standard insulin therapy and monitoring.
That is a different clinical question. MSC therapy for Type 2 diabetes targets insulin resistance and beta cell exhaustion rather than autoimmune destruction. Published evidence (Level 2–3) shows more consistent results in T2D than T1D, including improvements in fasting glucose, HbA1c, and insulin sensitivity.
A fasting C-peptide blood test measures endogenous insulin production. Any value above 0.2 nmol/L (0.6 ng/mL) suggests some residual beta cell function. Your endocrinologist can order this simple blood test.